Wells Fargo raises Marvell stock price target on AWS Trainium growth

Wells Fargo raised Marvell’s price target to $195 from $135 while keeping an Overweight rating, citing strong AWS Trainium-driven growth and Custom XPU revenue that could accelerate to 2x year-over-year growth in fiscal 2028. The firm estimates Trainium-only revenue could reach $5.5 billion to $6 billion-plus annually, versus current fiscal 2027/fiscal 2028 estimates of $2.15 billion and $4.57 billion. Additional analyst targets from RBC and BofA at $200 reinforce positive sentiment ahead of Marvell’s earnings in 7 days.

Analysis

The market is beginning to treat MRVL less like a cyclical networking supplier and more like a toll road on hyperscaler custom silicon buildouts. The key second-order effect is not just higher top-line potential, but a re-rating of supply chain confidence across the AI infra stack: if AWS keeps expanding Trainium capacity at the pace implied, adjacent beneficiaries should include optical interconnect, advanced packaging, and memory bandwidth vendors, while generic GPU-exposed names face valuation pressure as “AI spend” becomes more fragmented across accelerators.

The biggest near-term risk is that the current setup is highly expectation-dependent into earnings. MRVL has likely pulled forward a large amount of good news, so any commentary that narrows the path from committed capacity to revenue recognition could trigger a multiple reset even if fundamentals remain strong. In other words, the stock may trade more on conversion rate and timing than on absolute demand; investors should focus on whether management confirms backlog-to-revenue visibility for FY27/FY28 rather than the headline growth framework.

A more contrarian read is that the market may be underestimating how much of this opportunity is already embedded in consensus for the broader AI semiconductor complex. If Trainium/maia deployment ramps slower than assumed, the beneficiary may be AWS and Microsoft via capex efficiency rather than MRVL via immediate revenue capture. That creates a classic “good story, stretched positioning” setup: the equity can still work, but the skew likely shifts toward buying dips post-print rather than chasing into the event.

Relative value favors names with cleaner AI monetization and less timing risk. NVDA remains the default quality compounder, but MRVL offers higher beta to custom-XPU adoption and thus higher upside if management confirms acceleration. The trade is best expressed around earnings with asymmetric structures, because the next leg is likely to be driven by guidance credibility, not simply target-price revisions.

Key Decisions for Investors

• Tactically long MRVL into earnings only via call spreads or risk-defined upside structures over the next 7-21 days; upside is meaningful if FY27/FY28 bridge is reaffirmed, but downside is sharp if conversion timing disappoints.
• Pair long MRVL / short a basket of weaker AI-enabling semis with less custom-silicon exposure over the next 1-3 months; this isolates hyperscaler-specific demand and reduces factor risk if the AI trade cools.
• Add NVDA on any post-earnings MRVL weakness if management confirms accelerating AI infra spending; use MRVL as a leading indicator for broader capex momentum rather than a standalone long-term core.
• Avoid chasing spot after the analyst-target upgrades; wait for either the print or a 5-8% pullback to improve entry, because the current setup is more likely to reward patience than momentum buying.
• Monitor AMZN/MSFT capex commentary over the next quarter; if both continue to signal expanding custom silicon commitments, MRVL’s multiple can sustain, but if either slows, de-rate MRVL first.